Part 2 of a three part study-- A Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-729 Administered by Subcutaneous Injection to Subjects with Chronic Hepatitis B Infection
Latest Information Update: 03 May 2023
At a glance
- Drugs Imdusiran (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; First in man
- Sponsors Arbutus Biopharma
Most Recent Events
- 27 Apr 2023 According to an Arbutus Biopharma media release, Man-Fung Yuen, D.Sc., M.D., Ph.D is principal investigator of this study
- 27 Apr 2023 According to an Arbutus Biopharma media release, data from this trial were presented as late-breaker oral presentations at the Global Hepatitis Summit 2023 in Paris.
- 27 Apr 2023 Results published in the Arbutus Biopharma Media Release